Don't miss the signal ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
 |
| A message from Interactive Offers | NanoViricides, Inc. (NYSE: NNVC) is a clinical-stage biotech company working on a broad-spectrum antiviral drug platform that could address multiple billion-dollar unmet needs — including RSV, COVID, Bird Flu, and now measles. Here's why we're watching it closely: - NNVC recently surged to a 6-month high
- Public float under 16M shares = room for explosive swings
- Just broke through major technical indicators — and triggered bullish signals
- NV-387 just entered Phase II trials per a May 14 disclosure
- Stanford research shows measles could become endemic — NNVC is now testing a potential treatment
- Sub-$30M market cap leaves tons of room for value appreciation if even one viral target succeeds We look for setups with real science, big market needs, and technical momentum — and NNVC is checking every box. Biotech names like this often go unnoticed… until they don't. Whether or not broader markets turn, pandemics and public health threats aren't waiting — and NNVC is aiming straight at the front lines with a novel platform. With recent momentum, multiple viral targets, and an unusually tight float, NanoViricides (NNVC) is one biotech to watch immediately. 🧬 Why NNVC Could Be a 2025 Biotech Sleeper Hit
This message is a PAID ADVERTISEMENT for NanoViricides, Inc. (NYSE American: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $7000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between May 30, 2025 and June 5, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc. (NYSE American: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
| | |
| |
Tidak ada komentar:
Posting Komentar